Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Buy” by Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned an average rating of “Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $7.1667.

A number of brokerages recently commented on RVPH. Maxim Group reduced their price objective on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, August 16th. Roth Capital restated a “buy” rating and issued a $3.00 price objective (down previously from $7.00) on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th. D. Boral Capital restated a “buy” rating and issued a $3.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. 683 Capital Management LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter valued at approximately $381,000. Armistice Capital LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter valued at approximately $1,026,000. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Persistent Asset Partners Ltd lifted its position in shares of Reviva Pharmaceuticals by 300.0% during the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after acquiring an additional 480,864 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after acquiring an additional 29,063 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ:RVPH opened at $0.5385 on Friday. The company has a market cap of $36.62 million, a P/E ratio of -0.83 and a beta of -0.05. Reviva Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $4.28. The company has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.85.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.